Skip to content

EBITDA at other companies

Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
-$1.62M-107%
LBR
LB Pharmaceuticals Inc Common StockLBRX
-$18.97M-263%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Johnson & Johnson logo
Johnson & JohnsonJNJ
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Operating income-$64.5M-174%
Net income-$60.7M-172%
EPS (diluted)-$1.34+95.4%

Balance sheet

See full
Cash & equivalents$55.7M
Total debt$5.6M
Total equity$399.8M+285%
Total assets$418.8M

Cash flow

See full
Operating cash flow-$51.2M-100%
CapEx$24.0K
Free cash flow-$51.2M

Valuation

See full
Market cap$1.45B+109%
Enterprise value$1.4B

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio22.9×

Where this comes from

Calculated from MapLight Therapeutics, Inc. ’s reported figures.

$64.5Mebit+
$162.0KDepreciation Depletion & Amortization
=-$64.34M

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's EBITDA?
MapLight Therapeutics, Inc. (MPLT) reported EBITDA of -$64.34M in Q1 2026.
How has MapLight Therapeutics, Inc. 's EBITDA changed year-over-year?
MapLight Therapeutics, Inc. 's EBITDA decreased by 175.2% year-over-year, from -$23.38M to -$64.34M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.